3Vote!
Xconomy (Free subscription) | 12/03/2009
Cambridge, MA-based Alkermes said today it is betting $10 million on a crosstown startup that it hopes has found a way to make the world’s best-selling rheumatoid arthritis drug more convenient for patients. Alkermes (NASDAQ: ALKS) has agreed to pay $2 million upfront for a license from Cambridge, MA-based Acceleron Pharma, make an $8 million equity [...]
3Vote!
MyDiabetesCentral.com - Latest Diabetes News (Free subscription) | 11/30/2009
The rheumatoid arthritis drug Rituxan may also help people who have recently been diagnosed with Type 1 diabetes, new research suggests.
5Vote!
The Street (Free subscription) | 11/10/2009
PRINCETON, N.J. (Bristol-Myers Squibb acquired worldwide rights to an experimental rheumatoid arthritis drug from privately held Alder Pharmaceuticals, the companies announced Tuesday. More from Adam Feuerstein The drug, ALD518, is an injectable monoclonal antibody that targets and blocks the production of IL-6, a molecule that plays role in the inflammation, swelling, pain...
5Vote!
Indy Star (Free subscription) | 11/04/2009
WASHINGTON -- A fast-growing category of prescription drugs that are among the most expensive on the market could, for the first time, face competition from generic competitors under the health-care bills moving through Congress.
4Vote!
aarkstore | 10/28/2009
Rheumatoid Arthritis Therapy Area Pipeline Report contains detailed information on the rheumatoid arthritis drug pipeline. This report provides insight into the pipeline status of rheumatoid arthritis drugs by company and by stage as well as a summary of the latest news and developments in this area. Scope of the report: Each Life Science Analytics’
4Vote!
Xconomy (Free subscription) | 11/16/2009
Trubion Pharmaceuticals, the Seattle-based company developing new drugs for autoimmune diseases and cancer, said today that its founding CEO, Peter Thompson, has resigned and director Steve Gillis of Arch Venture Partners will step in to fill the void as executive chairman. Trubion (NASDAQ: TRBN) said today that Thompson is leaving his positions as chairman, CEO and [...]
5Vote!
The Puget Sound Business Journal (Free subscription) | 11/10/2009
Alder Biopharmaceuticals Inc. said it’s signed a deal with Bristol-Myers Squibb Co. to commercialize the Bothell biotech’s rheumatoid arthritis drug. (BMY)
3Vote!
Xconomy (Free subscription) | 11/10/2009
Alder Biopharmaceuticals has just struck one of the biggest biotech partnerships of the year, both in the Seattle area and nationally. The Bothell, WA-based developer of faster and cheaper technology for making antibody drugs has formed a collaboration with Bristol-Myers Squibb (NYSE: BMY), focused on the development of Alder’s experimental rheumatoid arthritis drug,...
5Vote!
The Street (Free subscription) | 11/10/2009
... is being called "exceptional" by the analysts at Cowen. More updates to come... Bristol Licenses Arthritis Drug(At 9:20 AM ET) Bristol-Myers Squibb() acquired worldwide rights to an experimental rheumatoid arthritis drug from privately held Alder Pharmaceuticals, the companies announced Tuesday. The drug, ALD518, is an injectable monoclonal antibody that...
4Vote!
PR News Wire (Free subscription) | 11/02/2009
WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 98 percent of surveyed rheumatologists indicate they will prescribe Roche's Actemra, an interleukin-6 inhibitor, for the treatment of rheumatoid arthritis following the agent's expected launch in 2010. When asked why they...
3Vote!
Xconomy (Free subscription) | 11/10/2009
... has formed a collaboration with Bristol-Myers Squibb (NYSE: BMY ) to develop Alder’s experimental rheumatoid arthritis drug, ALD518, and the deal could be worth more than $1 billion. In exchange for granting Bristol a worldwide exclusive license to develop ALD518 for all uses except cancer, Alder will get $85 million upfront, as much as $764 million in development and regulatory...
11Vote!
Firedoglake (Free subscription) | 10/29/2009
There was much celebration on Capitol Hill today with the announcement of the new House health care bill. For myself, as a three-time breast cancer survivor, there was tremendous sadness and disappointment in the Speaker. Nancy Pelosi made a choice with regard to the lifesaving biologic drugs I took when I was in chemotherapy-drugs that [...]
10Vote!
The Huffington Post (Free subscription) | 10/29/2009
Pelosi made a choice about the lifesaving biologic drugs I took when I was in chemotherapy that will cost many fellow breast cancer survivors everything they own, and quite possibly their lives.
7Vote!
Miami Herald (Free subscription) | 10/22/2009
The deal is technically structured as a reverse merger, an obvious ploy to try to retain roughly $2 billion a year in revenue Schering-Plough gets from its partnership with Johnson & Johnson selling the rheumatoid arthritis drug Remicade and its successor, Simponi, which was approved this year in the U.S. and European Union. J&J is claiming that change of control of Schering-Plough...
3Vote!
Daily Advance - Business (Free subscription) | 10/20/2009
Biogen 3Q profit beats views on smaller chargesCAMBRIDGE, Mass. — Biogen Idec Inc. said Tuesday its profit jumped 34 percent in the third quarter due to lower amortization costs and increased sales of its multiple sclerosis drug Tysabri.The Cambridge, Mass., drugmaker said its profit rose to $277.6 million, or 95 cents per share, from $206.8 million, or 70 cents per share. Excluding one-time...
